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Zinc is a metal ion that is an essential cell signaling molecule. Highlighting this, zinc is an
insulin mimetic, activating cellular pathways that regulate cellular homeostasis and physio-
logical responses. Previous studies have linked dysfunctional zinc signaling with several dis-
ease states including cancer, obesity, cardiovascular disease and type 2 diabetes. The
present study evaluated the insulin-like effects of zinc on cell signaling molecules including
tyrosine, PRSA40, Akt, ERK1/2, SHP-2, GSK-3β and p38, and glucose oxidation in human
and mouse skeletal muscle cells. Insulin and zinc independently led to the phosphorylation
of these proteins over a 60-minute time course in both mouse and human skeletal muscle
cells. Similarly, utilizing a protein array we identified that zinc could active the phosphoryla-
tion of p38, ERK1/2 and GSK-3B in human and ERK1/2 and GSK-3B in mouse skeletal
muscle cells. Glucose oxidation assays were performed on skeletal muscle cells treated
with insulin, zinc, or a combination of both and resulted in a significant induction of glucose
consumption in mouse (p<0.01) and human (p<0.05) skeletal muscle cells when treated
with zinc alone. Insulin, as expected, increased glucose oxidation in mouse (p<0.001) and
human (0.001) skeletal muscle cells, however the combination of zinc and insulin did not
augment glucose consumption in these cells. Zinc acts as an insulin mimetic, activating key
molecules implicated in cell signaling to maintain glucose homeostasis in mouse and
human skeletal muscle cells. Zinc is an important metal ion implicated in several biological
processes. The role of zinc as an insulin memetic in activating key signaling molecules
involved in glucose homeostasis could provide opportunities to utilize this ion therapeutically
in treating disorders associated with dysfunctional zinc signaling.
Introduction
Insulin resistance is a common pathophysiological condition in which patients present with per-
turbed biological responses to endogenous insulin leading to compromised glucose homeostasis
specifically in liver and skeletal muscle [1]. The contribution of insulin resistance in various dis-
eases such as type 2 diabetes (T2D), obesity, liver cirrhosis, atherosclerosis and cardiovascular
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disease [1, 2] is highly significant. A foremost concern for people with insulin resistance is the pro-
gressive failure of pancreatic β-cell function (a major determinant of type 2 diabetes progression)
and compromised insulin secretion. Therefore, prevention strategies that take advantage of this
“window of opportunity” (before β-cell failure) to prevent or lessen disease progression would
have an enormous impact on the health and wellbeing of our communities. Currently, zinc is
being investigated for its role in cell signaling pathways that are amendable to glucose homeostasis
and thus have implications for insulin resistance and type 2 diabetes [3].
Zinc is present in all parts of the body including organs, tissues, fluids and secretions [4]
and plays a critical role in a wide variety of biological processes [5, 6]. For example, zinc has a
unique and extensive role in nucleic acid and lipid metabolism, cell signaling, growth and dif-
ferentiation, apoptosis, enzyme activity, and brain and immune function [7]. Normal zinc
homeostasis has a critical role in the release and action of insulin to maintain glucose homeo-
stasis [8] since zinc has insulin mimetic activity and controls cellular processes including insu-
lin receptor signal transduction, and insulin storage and secretion [9].
Zinc is essential for the processing, crystallization, and storage of insulin in pancreatic β-
cells through the function of the pancreatic zinc transporter ZnT8 that moves zinc into insulin
secretory cells [10, 11]. Beta-cell specific ZnT8 knock out mice display glucose intolerance,
abnormal β-cell morphology, reduced islet insulin processing, a reduction in the total number
of granules, and an increase in empty atypical granules suggesting that insulin crystallization
and packaging is compromised [10]. In fact, there is a strong association between a mutation
in ZnT8 (an arginine is replaced with a tryptophan at position 325 [R325W] in the cytoplasmic
domain) which increases the risk of type 2 diabetes [12,13].
Early studies on zinc’s insulin mimetic activity revealed that this metal ion increased
glucose metabolism in isolated rat adipocytes [14]. Similarly, in 3T3-L1 adipocyte cells, zinc
treatment increased tyrosine phosphorylation of the insulin receptor β subunit and phosphor-
ylation of Akt, and this was concomitant with enhanced glucose transport, independent of
insulin [15]. These studies were further supported in C2C12 skeletal muscle cells where zinc
could phosphorylate tyrosine, and the insulin receptor substrate 1 (ISR1) in the absence of
insulin [16]. Moreover, zinc stimulated glucose consumption in normal and insulin-resistant
L6 myotubes and was concomitant with the upregulation of Akt, the translocation of Glut4
and the phosphorylation of Gsk3β [17]. In delineating the mechanism whereby zinc exerts its
effect on tyrosine phosphorylation, it was shown that zinc can increase tyrosine phosphoryla-
tion by inhibiting tyrosine phosphatases in C6 glioma cells [18,19]. These data are supported
by recent studies that showed zinc ions inhibited PTP1B activity through direct binding to the
enzyme [20]. These above studies on zinc as an insulin mimetic relay important information
into the complexities of the role of this metal ion in signaling pathways and provide justifica-
tion to further explore these pathways in more detail in metabolic processes associated with
glycemic control.
Given the role of zinc as an insulin mimetic in controlling cellular metabolism, we sought
to delineate the role of this metal ion in cellular processes amendable to controlling glucose
homeostasis in skeletal muscle cells. We identified that in mouse and human skeletal muscle
cells, zinc could affect several insulin-dependent cell signaling pathways that was concomitant
with increased glucose oxidation.
Materials and methods
Antibodies
Akt (#9272), phospho-Akt (Ser473; #4058), phosphor-p44/42 MAPK (Erk1/2, Thr201/Tyr204;
#8544), phospho-p44/42 MAPK (Eek1/2; #9102), SHP-2 (#3752), phospho-SHP-2 (Tyr580;
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#3703), phospho-Tyrosine (P-Tyr-100; #5465), GAPDH (#2118), and HRP-linked secondary
antibodies (Anti-rabbit #7074; Anti-mouse #7067) were obtained from Cell Signaling Technol-
ogy, USA. Intracellular signaling array kit (PathScan #7323) was also purchased from Cell Sig-
naling Technology.
Cell culture
Mouse C2C12 cells (a generous gift from Professor Steve Rattigan, Menzies Institute for Medi-
cal Research, Hobart, Australia) and human skeletal muscle cells (Thermo Fisher, Australia;
catalog number A12555) were cultured in DMEM (Thermo Fisher) medium containing 10%
fetal calf serum (FCS) and 100 U/mL penicillin/streptomycin (Thermo Fisher) and were main-
tained at 37˚C and 5% CO2 in a humidified atmosphere. Cells were treated with insulin (10
nM), zinc (20 μM) and/or zinc pyrithione (10 μM) (Sigma Aldrich, Australia) for 60 minutes.
The dose of zinc used is consistent with previous studies [21–23, 3] and represents the physio-
logical level of plasma zinc which can range from 10.7 μM following a morning fast to 21.1 μM
in healthy individuals [24].
Seventy-two hours before treatment, skeletal muscle cells were differentiated into myotubes
by the addition of media containing 2% horse serum (Thermo Fisher). Three hours before
treatments, the cells were exposed to serum-free conditions.
Immunoblot analysis
Whole cell lysates were prepared in RIPA Lysis buffer in the presence of protease and protein
phosphatase inhibitors (Thermo Fisher). Lysates were vortexed every 10 minutes for 1 hour at
4˚C, and centrifuging at 15000 rpm for 5 minutes. Protein concentrations of the supernatants
were determined using the BCA assay kit as per manufacturer’s instructions (Thermo Fisher).
For western blotting analysis, equal amounts of proteins were heated to 95˚C, separated on
4–15% SDS-polyacrylamide gels (Bio-Rad, Australia) and wet transferred to PVDF at 200 mV
for 1 hour at 4˚C (Polyvinylidene Difluoride) membranes (Thermo Fisher). The membrane
was then blocked 2 hours in TBST (50 mmol/L Tris-Cl, pH 7.6, 150 mmol/L NaCl and 0.1%
Tween 20) containing 5% (w/v) casein, and then incubated with the appropriate primary anti-
body as indicated overnight at 4˚C. The membrane was washed four times with TBST, then
incubated with HRP-conjugated secondary antibody for 1 hour. The membrane was again
washed four times with TBST, and the blots were developed using SuperSignal West Femto kit
[25] (Thermo Fisher). All phosho-immunoreactive species, Akt, ERK, SHP were normalized
against total Akt, ERK or SHP. Immunoreactive phospho-tyrosine was normalized to
GAPDH.
Intracellular signaling array
The intracellular signaling protein array kit (chemiluminescent Readout) is a slide-based anti-
body array founded upon the sandwich immunoassay principle. The array kit allows for the
simultaneous detection of 18 important signaling molecules when phosphorylated or cleaved.
Skeletal muscle cells were treated with 10 nM insulin, 20 μM ZnSO4 in the presence of 10 μM
sodium pyrithione (NaPy), 20 μM ZnSO4 alone, or no treatment (as a control) over 30 minutes
and cells were lysed in RIPA lysis buffer supplemented with protease and protein phosphatase
inhibitors. The assay procedure was performed according to the manufacturer’s protocol.
Briefly, cell lysates were incubated on the array slide followed by a biotinylated detection anti-
body cocktail. Streptavidin-conjugated HRP and LumiGLO reagent were then used to visualize
the bound detection antibody by chemiluminescence. An image of the slide was captured with
a digital imaging system. Spot intensities for each phosho-immunoreactive protein in the
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insulin and zinc treated extracts were normalized to their untreated control. The image was
analyzed, and the spot intensities quantified using densitometry array analysis software, Image
J (https://imagej.nih.gov/ij/).
Glucose oxidation assay
To determine the amount of glucose consumption by cells, glucose oxidase (GOx) activity
assay kit was used as per manufacturer’s instructions (Sigma). To establish the glucose oxida-
tion assay, cells were cultured in 96 well plate to reach 100% confluence. As the assay medium
should be without any exogenous fuel substrate supplementation, cells were cultured in the
serum-free media for another 24 hours. After 24 hours serum-free condition, cells were treated
with 10 nM insulin, 20 μM of ZnSO4 in the presence of 10 μM NaPy, a combination of 10 nM
insulin and 20 μM ZnSO4 in the presence of 10 μM pyrithione, and DMEM alone as a control.
The concentration of glucose added to initiate glucose oxidation was 10 mM, which was deter-
mined in preliminary experiments to be above saturation. After incubation for 3 hours, cell
lysate was collected and reaction mixture (GOx assay buffer, GOx developer, fluorescent per-
oxidase substrate and GOx substrate) was added and the absorbance was measured at 570 nm
using a TECAN infinite M200 PRO flow cytometer. The background was corrected subtract-
ing the blank measurement value from the sample measurement value.
Insulin receptor inhibition
C2C12 skeletal muscle cells were treated with an insulin receptor tyrosine kinase inhibitor
HNMPA-(AM)3 (abcam, Australia) at 0, 25, 50 and 100 μM for 1 hour followed by treatment
of cells with either insulin (100 nM) for 30 mins, or zinc (20 μM) plus NaPy (10 μM) for 30
minutes. Following treatment, whole cell lysates were prepared and immunoblot analysis was
performed on pAkt and total Akt as previously described in the methods above.
Statistical analysis
Data, represented as the means ± SEM, were analyzed by the one-way ANOVA for multiple
comparisons using the Graph Pad Prism 5 software to determine any significant differences.
P< 0.05 was considered significant.
Results
Effect of zinc on insulin-dependent cell signaling molecules Akt, Tyrosine,
SHP, ERK1/2, and PRAS40
We measured the phosphorylation status of several proteins implicated in the insulin-signaling
cascade in the presence of insulin or zinc. To assess that skeletal muscle cells responded to
insulin we measured the phosphorylation status of protein kinase B (Akt), a well-established
protein that is phosphorylated in the presence of insulin [26]. Skeletal muscle cells were treated
with 10 nM insulin over 60 minutes and subsequent western blots were performed for the
immunoreactivity of p-Akt. We observed that 10 nM of insulin-activated p-Akt in both C2C12
mouse and human skeletal muscle cells and thus confirmed our cells responded to insulin
treatment (Fig 1). To test whether zinc has insulin mimetic activity to induce the phosphoryla-
tion of Akt, skeletal muscle cells were also treated with 20 μM ZnSO4 in the presence of 10 μM
pyrithione. Similarly, zinc induced the phosphorylation of Akt within 15 minutes of treatment
in both mouse and human cell lines (Fig 1).
The components of the mitogen-activated protein kinase/extracellular signal-regulated pro-
tein kinase (MAPK/ERK) pathway are modifiers of cellular insulin responsiveness [27], and
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therefore sensitive to insulin. Accordingly, we compared the phosphorylation status of ERK1/2
in cells treated with insulin and ZnSO4. Insulin induced the phosphorylation of ERK1/2 within
15 minutes of treatment in mouse and human skeletal muscle cells (Fig 2). Similarly, ZnSO4 in
the presence of pyrithione induced ERK phosphorylation within 15 minutes of treatment in
these cell lines (Fig 2).
We also identified that treatment of mouse and human skeletal muscle cells with insulin
and zinc led to the phosphorylation of SHP-2, a protein tyrosine phosphatase involved in insu-
lin signaling pathway [28] (Fig 3). Insulin and ZnSO4 induced pSHP-2 within 30 minutes of
treatment in mouse and human skeletal muscle cells. pSHP-2 increased at 60 minutes of treat-
ment in the human skeletal muscle cells, but not in mouse skeletal muscle (Fig 3).
Fig 1. Analysis of p-Akt in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total Akt was used as an internal loading control in both panels and levels of pAKT were
normalized to total Akt.
https://doi.org/10.1371/journal.pone.0191727.g001
Fig 2. Analysis of p-ERK in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total ERK was used as an internal loading control in both panels and levels of p-ERK were
normalized to total ERK.
https://doi.org/10.1371/journal.pone.0191727.g002
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The activation and/or transduction of many signaling pathways including insulin signaling
depends on the phosphorylation of tyrosine [29]. To test whether zinc plays a role in the phos-
phorylation of tyrosine residues in skeletal muscle, we treated mouse and human cells with
insulin or ZnSO4 over 60 minutes. Insulin and ZnSO4 induced the phosphorylation of tyrosine
residues over the time course in both mouse and human skeletal muscle cell lines (Fig 4).
We also detected significant changes in the phosphorylation of Akt, ERK1/2, glycogen syn-
thesis kinase-3 (GSK-3β), Protein-Rich Akt Substrate of 40 kDa (PRAS40), and p38 using an
Intracellular signaling protein array (Table 1 and Fig 5A and 5B). Positive signals for PRSA40,
ERK1/2, Akt and GSK-3β were detected in skeletal muscle cells in the mouse protein array
when compared to the control panel. Insulin activated PRAS40 and Akt, while ZnSO4 acti-
vated PRAS40, ERK1/2, Akt and GSK-3β in this system (Fig 5A). In the human protein array,
we observed that insulin activated ERK1/2, Akt and PRAS40 when compared to the control.
ZnSO4 activated ERK1/2, Akt, GSK-3β and p38 but not PRAS40 in this instance (Fig 5B).
Fig 3. Analysis of p-SHP in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total SHP was used as an internal loading control in both panels and levels of p-SHP were
normalized to total SHP.
https://doi.org/10.1371/journal.pone.0191727.g003
Fig 4. Analysis of p-tyrosine in mouse and human skeletal muscle cells treated with insulin, ZnSO4, and NaPy
over 60 min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in
minutes from 0, 15, 30 and 60 and GAPDH was used as an internal loading control in both panels and levels of p-
tyrosine were normalized to GAPDH.
https://doi.org/10.1371/journal.pone.0191727.g004
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Densitometry was performed on the protein arrays to determine the level of protein expres-
sion between the insulin and ZnSO4 treatment and the control. In mouse skeletal muscle cell
lines, Akt and ERK1/2 protein expression was significantly higher (p< 0.01 and p<0.001
respectively) in the ZnSO4 treated cells when compared to the control (Fig 6A and 6B, respec-
tively). GSK-3β expression and activation play a critical role in mammalian cells and impacts
various cellular processes including glycogen synthesis and glucose transport [30]. The GSK-
3β protein levels were significantly higher (p<0.001) in cells treated with ZnSO4 compared to
control (Fig 6C). PRAS40, another important cell signaling molecule, is among the most
prominent Akt and mTOR complex 1 (mTORC1) substrates being phosphorylated in response
to growth factor stimulation such as insulin in eukaryotes [31]. The PRAS40 protein expres-
sion was also significantly higher (p<0.001) in mouse cells treated with ZnSO4 when com-
pared to control (Fig 6D).
In the human cell lines, pAkt expression was significantly different (p<0.001) over the con-
trol during ZnSO4 and insulin treatment (Fig 7A). Similarly, pERK1/2 protein expression was
significantly different for ZnSO4 treatment (p<0.01) and insulin treatment (p< 0.001) over
Table 1. Protein target map of intracellular signaling array (cell signaling).
Positive control ERK1/2 ERK1/2 Stat1 Stat1 Positive control
Stat3 Stat3 Akt (Thr308) Akt (Thr308) Akt (Ser473) Akt (Ser473)
AMPKα AMPKα S6 Ribosomal Protein S6 Ribosomal Protein mTOR mTOR
HSP27 HSP27 Bad Bad p70 S6 Kinase p70 S6 Kinase
PRAS40 PRAS40 p53 p53 p38 p38
SAPK/JNK SAPK/JNK PARP PARP Caspase-3 Caspase-3
Positive control GSK-3β GSK-3β Negative control Negative control Negative control
https://doi.org/10.1371/journal.pone.0191727.t001
Fig 5. Effect of insulin and zinc on intracellular proteins via analysis of an intracellular protein array (see
Table 1). a. Mouse skeletal muscle cells. Top panel, control (untreated cells), middle panel, insulin treated cells; bottom
panel, ZnSO4 treated cells. Positive and negative controls are shown labelled on the control panel. Significant responses
to insulin and ZnSO4 (PRAS40, Akt, ERK1/2 and GSK-3β) are shown. b. Human skeletal muscle cells. Top panel,
control (untreated cells), middle panel, insulin treated cells; bottom panel, ZnSO4 treated cells. Positive and negative
controls are shown labelled on the control panel. Significant responses to insulin (PRSA40, Akt and ERK1/2) and
ZnSO4 (Akt, ERK1/2, GSK-3β and p38) are shown. All positive signaling molecules in the insulin and zinc treated
arrays were normalized to their corresponding signaling molecule on the control array (no treatment).
https://doi.org/10.1371/journal.pone.0191727.g005
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that of the control (Fig 7B). The GSK-3β protein level was also significantly higher when
treated with zinc (p< 0.001) than insulin treatment (p<0.05) and when compared to the con-
trol group (Fig 7C). There was no significant difference in the levels of PRAS40 when treated
with ZnSO4 and compared to the control (Fig 7D). However, insulin treatment resulted in a
significant increase (p< 0.001) in PRAS40 compared to the control group. Lastly, ZnSO4 treat-
ment resulted in a significant increase in p38 (p< 0.001) over the control group but there was
no significance identified during the insulin treatment (Fig 7E). p38, is another signaling factor
that plays a significant role in the regulation of glucose transport [32].
Fig 6. Densitometry results from Fig 5 protein array in mouse skeletal muscle cells. a. pAkt, b. pERK1/2, c. GSK-3β,
and d. PRAS40. Control (untreated cells), ZnSO4 and insulin treatments are shown. Differences between the
expressions of proteins in cells were determined by one-way ANOVA. The results of 3 independent experiments are
presented as a mean ± standard error. p< 0.05,  p< 0.01 and  p<0.001 considered significant when compared
to the control.
https://doi.org/10.1371/journal.pone.0191727.g006
Fig 7. Densitometry results from Fig 5 protein array in human skeletal muscle cells. a. pAkt, b. pERK1/2, c. pGSK-
3β, d. PRAS40, and e. p38. Control (untreated cells), ZnSO4 and insulin treatments are shown. Differences between the
expressions of proteins in cells were determined by one-way ANOVA. The results of 3 independent experiments are
presented as a mean ± standard error.  p< 0.05,  p< 0.01 and  p<0.001 considered significant when compared
to the control.
https://doi.org/10.1371/journal.pone.0191727.g007
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Zinc effect of glucose consumption in mouse C2C12 and human skeletal
muscle cells
It is clear that zinc affects several cell signaling molecules, analogous to insulin signaling, that
are implicated in glucose homeostasis in skeletal muscle. Accordingly, we tested whether zinc
could activate glucose oxidation in both mouse and human skeletal muscle cells. Initially we
tested glucose oxidation in the presence of insulin treatment, and as expected, insulin signifi-
cantly induced glucose oxidation in mouse (p< 0.001) and human (p< 0.001) skeletal muscle
cells compared to the untreated cells (Fig 8A and 8B). Similarly, ZnSO4 significantly induced
glucose oxidation in both mouse (p< 0.01) and human (p< 0.05) skeletal muscle cells com-
pared to the untreated control (Fig 8A and 8B). We did not observe a significant additive effect
of insulin and ZnSO4 treatment together when compared to ZnSO4 or insulin treatment alone.
Zinc activation of pAKT potentially acts through a functional insulin
receptor
Given that we did not observe an additive effect of insulin and ZnSO4 treatment together on
glucose oxidation, we sought to determine whether a functional insulin receptor is required to
facilitate zinc activation of pAkt. To address this, we utilized C2C12 skeletal muscle cells
treated with an insulin receptor tyrosine kinase inhibitor in the presence of insulin or zinc. We
observed that 50 μM of the insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 was suf-
ficient to inhibit insulin-induced pAkt (Fig 9). Similarly, we identified that 25 μM of HNMPA-
(AM)3 inhibited zinc-induced pAkt and this was completely abolished at 50 and 100 μM of
HNMPA-(AM)3 (Fig 9).
Discussion
In this study, we analyzed the effects of zinc on insulin signaling in mouse and human skeletal
muscle cell lines. Insulin signaling is an important and highly conserved regulatory network
coordinating metabolism and growth in multicellular organisms [33]. Dysregulation of insulin
signaling is common in metabolic disorders. For example, insulin resistance which is a hall-
mark of type 2 diabetes mellitus [33], is characterized by a reduced insulin-mediated activation
of the PI3K/Akt pathway regulating glucose uptake [34]. Several studies have suggested that
zinc, as an essential trace element, has a potent ability on glucose handling by promoting beta
cell function and insulin sensitivity [35]. Zinc in skeletal muscle accounts for most of the
Fig 8. Glucose oxidation assay in the presence of insulin and ZnSO4. a. Mouse skeletal muscle cells, and b. Human
skeletal muscle cells. The results of 3 independent experiments are presented as a mean ± standard error.  p< 0.05, 
p< 0.01 and  p<0.001 considered significant compared with the control (untreated cells).
https://doi.org/10.1371/journal.pone.0191727.g008
Zinc modulates glycemic control in skeletal muscle
PLOS ONE | https://doi.org/10.1371/journal.pone.0191727 January 26, 2018 9 / 15
whole-body zinc (approximately 60%) [36], and as skeletal muscle is the major site of periph-
eral insulin resistance [37], we investigated the effects of zinc signaling in skeletal muscle cells.
Regarding the participation of zinc in insulin signaling, it is emphasized that this metal ion
promotes activation of phosphatidylinositol protein 3-kinase and protein kinase B (Akt),
increasing transport of glucose uptake to cells [38]. Our data shows that there is an increase in
the phosphorylation of Akt in mouse C2C12 and human skeletal muscle cells treated with
zinc, indicating the role of zinc in the induction of Akt phosphorylation. During insulin signal-
ing, the activated insulin receptor kinase, phosphorylates tyrosine residues on insulin receptor
substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2) and this subsequently generates a
tyrosine phosphorylation cascade to transmit the insulin signal [39]. Our data show that there
is an increase in phospho-tyrosine in both mouse and human skeletal muscle cell treated with
zinc and suggests that zinc also plays a role in transmitting the insulin signal.
Previous studies have shown that SHP-2 can bind to IRS-1 in response to insulin and mod-
ulate receptor tyrosine kinase-mediated signaling [40]. Our data indicates that zinc can also
activate SHP-2 in mouse and human skeletal muscle cells. Similarly, studies have shown that
the ERK/MAP kinase signaling pathway is an important mediator in insulin responsiveness
[41]. According to our results, zinc increases the expression of ERK in both cell lines which
might help to improve insulin signaling in skeletal muscle.
Our results have also shown that zinc exhibited insulin-like glucose transporting effects by
phosphorylation of key proteins involved in the insulin signaling cascade including GSK-3β.
GSK-3β plays several important roles in mammalian cells, and impacts such diverse cellular
processes including glycogen synthesis and glucose transport. Overactivity of GSK-3β in skele-
tal muscle of obese type 2 diabetic humans is associated with an impaired ability of insulin to
activate glucose disposal and glycogen synthase [42]. Studies have also demonstrated that inhi-
bition of non-phosphorylated form of GSK-3 can improve insulin-stimulated glucose trans-
port activity through enhanced post-insulin receptor insulin signaling and GLUT-4 glucose
Fig 9. Effect of insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 on insulin and zinc-induced pAkt. Mouse C2C12 skeletal
muscle cells were treated with increasing concentrations (0, 25, 50, and 100 μM) of HNMPA-(AM)3 followed by either treatment with insulin
(10 nM) or zinc (20 μM) for 1 hour. Concentrations of HNMPA-(AM)3 are given at 0, 25, 50 and 100 μM. Top panel: insulin-treated
measurement of pAkt, Lower panel: zinc-treated measurement of pAkt. Total Akt was used as an internal loading control in both panels and
levels of pAKT were normalized to total Akt.
https://doi.org/10.1371/journal.pone.0191727.g009
Zinc modulates glycemic control in skeletal muscle
PLOS ONE | https://doi.org/10.1371/journal.pone.0191727 January 26, 2018 10 / 15
transporter translocation [43]. Accordingly, GSK-3β serine phosphorylation, which is the inac-
tive form of GSK-3β, increased after treating cells with zinc.
Our data indicate that zinc increases PRAS40 in mouse skeletal muscle cells. PRAS40 is a
regulator of insulin sensitivity which has an inhibitory effect on mTOR and consequently
decreases mTOR expression which is a negative regulator of IRS1 in mouse skeletal muscle cell
line. It causes an abundance in IRS1 and enhances insulin-mediated Akt phosphorylation and
increases glucose uptake [44].
Activation of p38 is not only dependent on stimulus, but on cell type as well. For example,
insulin can stimulate p38 in 3T3-L1 adipocytes, but down-regulates p38 activity in chick fore-
brain neuron cells [45]. We have reported that the expression of p38 increases in human skele-
tal muscle cells treated with zinc. Although p38 phosphorylation has been reported to be
increased in response to insulin in skeletal muscle from non-diabetic subjects [46], we did not
observe this in our experiments. It is not clear why p38 did not respond to insulin in this
study. Possibly, the thirty-minute, insulin treatment time-point used on the protein arrays
missed the maximum response for p38. For example, treatment of mouse L6 myotubes with
100 nM insulin resulted in a maximum p38 response at ten minutes which declined at fifteen
minutes of treatment [47]. Similarly, in rat vascular smooth muscle cells (VSMC), p38 was rap-
idly activated in the presence of insulin at five minutes and quickly declined to basal levels at
fifteen minutes [48]. We also identified that zinc can oxidize glucose in both mouse and
human skeletal muscle cells. A previous study in rat adipocytes showed that zinc could
enhance the metabolism of glucose which was indicative of enhancement of facilitated glucose
transport [49]. While both insulin or zinc could independently activate glucose oxidation, an
additive effect of insulin and zinc was not observed. Additionally, we found that inhibition of
insulin receptor tyrosine kinase activity abolished the ability of insulin and zinc to activate
pAkt and therefore suggests that zinc potentially acts through the insulin signaling pathway.
These data are supported by previous studies where co-incubation with zinc and insulin did
not enhance glucose consumption in normal L6 cells and suggests that zinc and insulin may
act through the same downstream pathways [17]. However, in insulin-resistant L6 myotubes,
zinc and insulin together could enhance glucose consumption when compared to insulin treat-
ment alone [17]. These data suggest that disrupted insulin signaling in the insulin resistant L6
cells respond differently to zinc than in normal L6 cells and therefore might provide clues on
alternative signaling pathways under zinc stimulation.
Skeletal muscle is of major importance in insulin resistance and T2DM as it accounts for
85% of whole body insulin-dependent glucose uptake and therefore plays a critical role in
maintaining systemic glucose metabolism [37]. Defects in glucose metabolism in insulin resis-
tant skeletal muscle include reduced insulin receptor tyrosine phosphorylation [50] decreased
Akt phosphorylation [51–52], and impaired GLUT4 translocation [52,53]. These insulin pro-
tein targets are also activated by zinc treatment in skeletal muscle [3,17,54].
The ability of zinc to regulate insulin signaling processes suggests that this metal ion might
have utility to be targeted experimentally to improve the management and/or treatment of insu-
lin resistance. One well-studied target of the insulin-mimetic effects of zinc is protein tyrosine
phosphatase 1B (PTP1B). This phosphatase has a key role in the regulation of insulin action by
dephosphorylating the insulin receptor and insulin receptor substrates 1 and 2, thereby inhibit-
ing the insulin signaling cascade [55]. It is well-established that zinc can inhibit PTP1B which
affects insulin signaling [18]. Moreover, PTP1B knockout mice are highly sensitive to insulin,
have low adiposity, and are protected from diet-induced obesity [56]. These studies highlight
the dynamic role of zinc in insulin signaling processes and therefore offers opportunities to be
further investigated. Type 2 diabetes mellitus is increasing globally and is approaching pan-
demic levels. Current strategies for prevention are limited in scope and effectiveness, and the
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persistently high prevalence of T2DM confirm the shortfalls of available therapeutic options.
The ‘window of opportunity’ that presents before the loss of β-cell function and the develop-
ment and progression of T2DM suggests that a strategy aimed at reversing insulin resistance
would have major clinical outcomes and benefits for health and wellbeing. From a therapeutic
perspective, it is important that the molecular mechanisms of dysfunctional zinc transport and
defective zinc compartmentalization are identified in human skeletal muscle cells. Similarly,
characterizing how zinc leads to increased glucose homeostasis is paramount to understanding
potential intervention strategies where zinc transport could be manipulated experimentally to
improve glucose metabolism in patients with insulin resistance or T2DM.
Conclusions
Zinc is an essential metal ion implicated in several biological processes. Dysfunctional zinc sig-
naling is associated with various disease states. We have shown that zinc independently acti-
vates insulin signaling pathway proteins in mouse and human skeletal muscle cell lines. The
subsequent phosphorylation events associated with insulin signaling and increased glucose
oxidation was also mirrored with zinc treatment leading to the supposition that both insulin
and zinc are critically important in maintaining glucose homeostasis in skeletal muscle.
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